TICTOCNCT05156892
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion date changed from estimate of Jan 1, 2026 to Nov 1, 2026 Show 6 more changesShow less
- Eligibility criteria expanded, about 33 words
- Trial completed
- Final enrollment: 12 participants (planned 44)
- Secondary endpoints: details revised at 2 of 9 entries
- Site details revised
- Collaborators: details revised at 1 of 4 entries
- Notable Primary completion date: Jan 1, 2024 to Jan 1, 2026
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: Jan 1, 2025 to Jan 1, 2027
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 1, 2022 to Sep 4, 2022
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Recommended phase 2 dose of Tamoxifen in combination with Suba-itraconazole
Timeframe: 1 years
Secondary (7)
To determine overall response rate as determined by RECIST V1.1 and GCIG CA125 response criteria
To determine the duration of response
Incidence of Treatment-Emergent Adverse Events via CTCAE v5.0
Serum concentration of tamoxifen and derivatives
Tissue concentration of tamoxifen and derivatives
Show 2 moreShow less
Serum concentration of itraconazole
Tissue concentration of itraconazole
Arms and interventions
Dose-escalation/ expansionExperimental
SUBA-itraconazole (oral 150mg twice daily) and escalating dose of Tamoxifen (oral once daily) then expansion cohort
Drugs: SUBA-itraconazole, Tamoxifen
Sites
1 site in 1 country
- Kinghorn Cancer Centre, St. Vincent's HospitalSydney, New South Wales, Australia